Mersana Therapeutics (NASDAQ:MRSN) Trading Up 3.7%
Mersana Therapeutics (NASDAQ:MRSN) Trading Up 3.7%
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating)'s stock price was up 3.7% during mid-day trading on Friday . The company traded as high as $6.66 and last traded at $6.66. Approximately 2,607 shares traded hands during trading, a decline of 100% from the average daily volume of 1,150,149 shares. The stock had previously closed at $6.42.
默薩納治療公司(納斯達克代碼:MRSN-GET Rating)週五午盤股價上漲3.7%,最高報6.66美元。全天約有2,607股股票易手,較平均日成交量1,150,149股下跌100%。此前該股收盤價為6.42美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
A number of research analysts have recently issued reports on MRSN shares. Wedbush reiterated an "outperform" rating on shares of Mersana Therapeutics in a research report on Tuesday, August 9th. SVB Leerink increased their target price on Mersana Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th. Finally, Robert W. Baird increased their target price on Mersana Therapeutics from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th.
一些研究分析師最近發佈了關於MRSN股票的報告。韋德布什在8月9日星期二的一份研究報告中重申了對Mersana治療公司股票的“跑贏大盤”評級。SVB Leerink在8月9日週二的一份研究報告中將Mersana Treateutics的目標價從13.00美元上調至14.00美元,並給予該公司“跑贏大盤”的評級。最後,Robert W.Baird在8月9日星期二的一份研究報告中將Mersana Treeutics的目標價從18.00美元上調至20.00美元,並給予該公司“跑贏大盤”的評級。
Mersana Therapeutics Stock Up 5.3 %
Mersana治療公司股價上漲5.3%
The stock has a market capitalization of $656.87 million, a price-to-earnings ratio of -2.76 and a beta of 1.75. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.18. The business's 50-day moving average is $6.88 and its two-hundred day moving average is $5.05.
該股市值為6.5687億美元,市盈率為-2.76倍,貝塔係數為1.75。該公司的速動比率為3.32,流動比率為3.32,債務權益比為0.18。該業務的50日移動均線切入位在6.88美元,200日移動均線切入位在5.05美元。
Institutional Trading of Mersana Therapeutics
Mersana治療公司的機構交易
Large investors have recently bought and sold shares of the business. Victory Capital Management Inc. purchased a new position in shares of Mersana Therapeutics during the 1st quarter worth $36,000. Quantbot Technologies LP purchased a new position in Mersana Therapeutics during the 1st quarter valued at about $37,000. Washington University purchased a new position in Mersana Therapeutics during the 2nd quarter valued at about $43,000. Virtu Financial LLC purchased a new position in Mersana Therapeutics during the 1st quarter valued at about $53,000. Finally, Point72 Hong Kong Ltd purchased a new position in Mersana Therapeutics during the 4th quarter valued at about $57,000. Hedge funds and other institutional investors own 95.12% of the company's stock.
大型投資者最近買賣了該公司的股票。勝利資本管理公司在第一季度購買了價值3.6萬美元的Mersana治療公司的新股票頭寸。Quantbot Technologies LP在第一季度購買了Mersana治療公司的一個新頭寸,價值約3.7萬美元。華盛頓大學在第二季度購買了Mersana治療公司的一個新頭寸,價值約43,000美元。Virtu Financial LLC在第一季度購買了Mersana Treeutics的一個新頭寸,價值約53,000美元。最後,Point72 Hong Kong Ltd在第四季度購買了Mersana Treeutics的新頭寸,價值約57,000美元。對衝基金和其他機構投資者持有該公司95.12%的股票。
About Mersana Therapeutics
關於Mersana Treeutics
(Get Rating)
(獲取評級)
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
Mersana治療公司是一家臨牀階段生物製藥公司,為未得到滿足需求的癌症患者開發抗體藥物結合物(ADC)。它開發了XMT-1592,一種針對NaPi2b表達腫瘤細胞的Dolasynten ADC,正在進行治療卵巢癌和NSCLC腺癌的I期臨牀試驗。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Mersana Therapeutics (MRSN)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Declining Profits Challenge the CarMax Value Proposition
- 免費獲取StockNews.com關於Mersana治療公司(MRSN)的研究報告
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat:回顧一週9/26-9/30
- 這是買入美光科技的難忘時刻
- 雷神工業走出谷底
- 利潤下降對CarMax價值主張的挑戰
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Mersana治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Mersana Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。